Enzon Pharmaceuticals Announces 1-for-100 Reverse Stock Split Effective March 24th, Prepares for Viskase Merger
Summary
Enzon Pharmaceuticals announced its 1-for-100 reverse stock split will be effective March 24, 2026, a necessary step for its pending merger with Viskase Companies, Inc.
Key Events
-
1-for-100 Reverse Stock Split Effective
The company's 1-for-100 reverse stock split will become effective on March 24, 2026, at 4:30 p.m. ET. Common stock is expected to begin trading on a split-adjusted basis on the OTCQB under the temporary symbol 'ENZND' starting March 25, 2026.
-
Reverse Split Required for Merger
The reverse stock split is a mandatory prerequisite for the completion of the previously announced merger with Viskase Companies, Inc., and related issuances of common stock for an outstanding exchange offer.
-
Section 382 Rights Agreement Extended
The company entered into the Eleventh Amendment to its Section 382 Rights Agreement, extending the Final Expiration Date from March 24, 2026, to March 26, 2026. This is a continuation of a series of extensions for this defensive measure.
Analysis
Enzon Pharmaceuticals has announced the effective date for its previously approved 1-for-100 reverse stock split, a critical step required for the completion of its merger with Viskase Companies, Inc. This action, while dilutive in nature, is essential for the company to proceed with the transformational merger and potentially improve its market standing. Investors should monitor the completion of the merger and the company's performance post-split and merger.
At the time of this filing, ENZN was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $0.02 to $0.13. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.